Zyla Life Sciences Forms 3, 4 and 5: Stock Options
Statements of beneficial ownership filed with the SEC by officers, directors and 10% owners: 12 rows in 2014. Transaction codes are the SEC's. Shares and prices are split-adjusted; the as-filed figure is underneath.
- 2014-12-04: Reporting owner LINDHARDT KARSTEN; Form 4; Security Stock Option (Right to Buy); Transaction A Grant, award or other acquisition pursuant to Rule 16b-3(d).
- 2014-12-04: Reporting owner Strobeck Mark; Form 4; Security Stock Option (Right to Buy); Transaction A Grant, award or other acquisition pursuant to Rule 16b-3(d).
- 2014-12-04: Reporting owner Dayno Jeffrey M.; Form 4; Security Stock Option (Right to Buy); Transaction A Grant, award or other acquisition pursuant to Rule 16b-3(d).
- 2014-12-04: Reporting owner Musial Stan; Form 4; Security Stock Option (Right to Buy); Transaction A Grant, award or other acquisition pursuant to Rule 16b-3(d).
| Transaction date | Reporting owner | Form | Security | Transaction | Shares | Price | Price that day | Filing |
|---|---|---|---|---|---|---|---|---|
| 2014-12-04 | LINDHARDT KARSTEN Officer (VP, Research & Development) | 4 | Stock Option (Right to Buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +40,000 40,000 owned after | $5.25 exercise price | 2014-12-08 | |
| 2014-12-04 | Strobeck Mark Officer (Chief Business Officer) | 4 | Stock Option (Right to Buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +40,000 40,000 owned after | $5.25 exercise price | 2014-12-08 | |
| 2014-12-04 | Dayno Jeffrey M. Officer (Chief Medical Officer) | 4 | Stock Option (Right to Buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +60,000 60,000 owned after | $5.25 exercise price | 2014-12-08 | |
| 2014-12-04 | Musial Stan Officer (Chief Financial Officer) | 4 | Stock Option (Right to Buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +40,000 40,000 owned after | $5.25 exercise price | 2014-12-08 | |
| 2014-12-04 | Radie Robert S Director, Officer (President and CEO) | 4 | Stock Option (Right to Buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +100,000 100,000 owned after | $5.25 exercise price | 2014-12-08 | |
| 2014-09-30 | WEAVER GREGORY L Director | 4 | Stock Option (Right to Buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +20,000 20,000 owned after | $5.70 exercise price | 2014-10-01 | |
| 2014-09-30 | Walbert Timothy P Director | 4 | Stock Option (Right to Buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +20,000 20,000 owned after | $5.70 exercise price | 2014-10-01 | |
| 2014-08-06 | Dayno Jeffrey M. Officer (Chief Medical Officer) | 4 | Stock Option (Right to Buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +75,000 75,000 owned after | $11.50 exercise price | 2014-08-07 | |
| 2014-06-09 | Walbert Timothy P Director | 4 | Stock Option (Right to Buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +667 667 owned after | $15.00 exercise price | 2014-06-11 | |
| 2014-06-09 | WEAVER GREGORY L Director | 4 | Stock Option (Right to Buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +667 667 owned after | $15.00 exercise price | 2014-06-11 | |
| 2014-03-19 holding as of filing | Walbert Timothy P Director | 3 | Stock Option (Right to Buy) Derivative · Direct | Holding | $18.83 exercise price | 2014-03-19 | ||
| 2014-02-05 | WEAVER GREGORY L Director | 4 | Stock Option (right to buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | −2,083 2,083 owned after | $12.00 exercise price | 2014-02-07 |